连续参加乳腺钼靶筛查对乳腺癌死亡率的有益影响:一项前瞻性研究
结果显示,与从未连续参加者相比,连续参加最近两次筛查的女性乳腺癌死亡风险降低49%(RR 0.51),诊断后10年内死亡风险降低50%(RR 0.50);仅参加一次或漏检一次者风险降低幅度较小。
要点
- 连续参加最近两次乳腺钼靶筛查者乳腺癌死亡风险显著低于从未连续参加者(RR 0.51)。
- 仅参加最近一次或漏检最近一次筛查者,死亡风险降低幅度小于连续参加者。
- 连续参加者诊断后10年内乳腺癌死亡风险也显著低于从未连续参加者(RR 0.50)。
诊断标准与关键数值
- 连续参加组 vs 从未连续参加组:乳腺癌死亡风险 RR 0.51(95% CI: 0.48, 0.55;P < .001),降低49%。
- 连续参加组 vs 从未连续参加组:诊断后10年内乳腺癌死亡风险 RR 0.50(95% CI: 0.46, 0.55;P < .001),降低50%。
- 仅参加最近一次组和仅参加前一次组的风险降低幅度小于连续参加组。
- 连续参加组上述两项结局风险均显著低于仅参加最近一次组或仅参加前一次组。
临床应用与阅片要点
- 阅片时可关注患者既往乳腺钼靶筛查的连续参与情况,连续参加最近两次筛查者乳腺癌死亡风险降低最明显。
- 漏检最近两次筛查中的任一次与显著更高的乳腺癌死亡风险相关,提示筛查连续性的重要性。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Previously, the risk of death from breast cancer was analyzed for women participating versus those not participating in the last screening examination before breast cancer diagnosis. Consecutive attendance patterns may further refine estimates. Purpose To estimate the effect of participation in successive mammographic screening examinations on breast cancer mortality. Materials and Methods Participation data for Swedish women eligible for screening mammography in nine counties from 1992 to 2016 were linked with data from registries and regional cancer centers for breast cancer diagnosis, cause, and date of death (Uppsala University ethics committee registration number: 2017/147). Incidence-based breast cancer mortality was calculated by whether the women had participated in the most recent screening examination prior to diagnosis only (intermittent participants), the penultimate screening examination only (lapsed participants), both examinations (serial participants), or neither examination (serial nonparticipants). Rates were analyzed with Poisson regression. We also analyzed incidence of breast cancers proving fatal within 10 years. Results Data were available for a total average population of 549 091 women (average age, 58.9 years ± 6.7 [standard deviation]). The numbers of participants in the four groups were as follows: serial participants, 392 135; intermittent participants, 41 746; lapsed participants, 30 945; and serial nonparticipants, 84 265. Serial participants had a 49% lower risk of breast cancer mortality (relative risk [RR], 0.51; 95% CI: 0.48, 0.55; P < .001) and a 50% lower risk of death from breast cancer within 10 years of diagnosis (RR, 0.50; 95% CI: 0.46, 0.55; P < .001) than serial nonparticipants. Lapsed and intermittent participants had a smaller reduction. Serial participants had significantly lower risk of both outcomes than lapsed or intermittent participants. Analyses correcting for potential biases made little difference to the results. Conclusion Women participating in the last two breast cancer screening examinations prior to breast cancer diagnosis had the largest reduction in breast cancer death. Missing either one of the last two examinations conferred a significantly higher risk. Published under a CC BY 4.0 license. Online supplemental material is available for this article. See also the editorial by Stephen A. Feig in this issue.
引用
- Duffy SW, Tabár L, Yen AM, et al. Beneficial Effect of Consecutive Screening Mammography Examinations on Mortality from Breast Cancer: A Prospective Study. Radiology. 2021. PMID: 33650900. doi:10.1148/radiol.2021203935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。